Title:
USE OF NAPHTHYLAMIDE COMPOUND IN TREATING DRUG-RESISTANT TUMORS
Document Type and Number:
WIPO Patent Application WO/2024/088275
Kind Code:
A1
Abstract:
The present invention relates to a use of a naphthylamide compound in treating drug-resistant tumors. Specifically, disclosed in the present invention is a use of a compound (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating drug-resistant tumors, especially temozolomide-resistant tumors and EGFR inhibitor-resistant tumors. Also disclosed in the present invention is that a compound (I) or a pharmaceutically acceptable salt thereof, when used in combination with an EGFR third-generation inhibitor ASK120067, can reverse EGFR inhibitor resistance.
Inventors:
XIE HUA (CN)
DUAN WENHU (CN)
DING JIAN (CN)
ZHAN ZHENGSHENG (CN)
GENG MEIYU (CN)
YANG HANYU (CN)
LV YONGCONG (CN)
FENG FANG (CN)
ZHAO QIAN (CN)
ZHANG YANG (CN)
DUAN WENHU (CN)
DING JIAN (CN)
ZHAN ZHENGSHENG (CN)
GENG MEIYU (CN)
YANG HANYU (CN)
LV YONGCONG (CN)
FENG FANG (CN)
ZHAO QIAN (CN)
ZHANG YANG (CN)
Application Number:
PCT/CN2023/126296
Publication Date:
May 02, 2024
Filing Date:
October 24, 2023
Export Citation:
Assignee:
SHANGHAI INST MATERIA MEDICA CAS (CN)
International Classes:
A61K31/416; A61K31/4188; A61P35/00
Foreign References:
| CN104860885A | 2015-08-26 | |||
| CN115215847A | 2022-10-21 | |||
| US20180036304A1 | 2018-02-08 | |||
| US20200246346A1 | 2020-08-06 | |||
| US20100087499A1 | 2010-04-08 |
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: